Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was FDA approved for the treatment of acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an…
Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was FDA approved for the treatment of acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an…